Lenalidomide Rowex (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma‑cell growth and dysplastic marrow clones.

• Multiple Myeloma: improves progression‑free survival and reduces disease burden in adult patients.
• Myelodysplastic Syndromes: decreases transfusion dependence and may modify disease course in patients with del(5q) cytogenetic abnormality.
• Relapsed or refractory Multiple Myeloma: provides therapeutic benefit after prior therapies have failed.

• Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors such as Ikaros and Aiolos. This leads to reduced cytokine production, inhibition of angiogenesis, and enhanced immune‑mediated tumor cell killing. The combined anti‑angiogenic, immunomodulatory, and direct anti‑tumor actions contribute to its efficacy in plasma‑cell disorders and myelodysplastic syndromes.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Neutropenia: lowered neutrophil count, increasing infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may lead to dehydration.
• Nausea: feeling of sickness often accompanied by vomiting.
• Rash: mild skin irritation or redness.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: markedly low neutrophil levels requiring medical intervention.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.
• Hepatotoxicity: significant liver enzyme elevations or liver injury.
• Severe infections: opportunistic infections that can be life‑threatening.

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risks.

• Pregnancy: contraindicated; drug is category X and can cause fetal harm.
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
• Renal impairment: evaluate kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and use caution in patients with liver disease.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias early.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure.
• Live vaccines: risk of infection due to immunosuppression.
• Anticoagulants (e.g., warfarin): heightened bleeding risk when combined with thrombosis prophylaxis.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce drug levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate neutropenia.
• Other immunomodulatory agents: additive immunosuppression may increase infection risk.